Healthcare / BiotechnologyNasdaqGS
$0.20
-0.03 (-14.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-159.2M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$46M
P/E
N/A
•EV/EBITDA
N/A
•ROE
138.8%
↑Gross Margin
N/A
•Debt/Equity
-1.65
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-353.5%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.5M · net income $-170.4M · FCF $-171.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $48.5M | $48.5M | $114.7M | — | — | — | — | — | — | — |
| Net Income | $-170.4M | $-170.4M | $-56.5M | $-179.8M | $-229.4M | $-234.0M | $-243.4M | $-180.3M | $-147.0M | $-6.8M |
| EBITDA | $-158.5M | $-158.5M | $-40.0M | $-161.9M | $-211.1M | $-214.4M | $-232.6M | $-185.2M | $-148.7M | — |
| EPS | -0.75 | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 | — | — |
| Operating Margin | -336.8% | -336.8% | -52.2% | — | — | — | — | — | — | — |
| Net Margin | -351.5% | -351.5% | -49.3% | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | -1.65 | -1.65 | 6.88 | 3.38 | 18.69 | 0.24 | 0.09 | 0.08 | — | — |
| Current Ratio | 2.20 | 2.20 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-171.3M | $-171.3M | $-3.5M | $-159.2M | $-187.5M | $-190.4M | $-177.9M | $-147.8M | $-54.5M | — |
| Returns | ||||||||||
| ROE | 138.8% | 138.8% | -191.7% | -286.5% | -1899.3% | -192.7% | -75.9% | -51.2% | 122.4% | 98.7% |
| Valuation | ||||||||||
| P/B | — | — | 7.82 | 2.07 | 15.41 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -57.7% | -57.7% | — | — | — | — | — | — | — | — |
| EPS Growth | -200.0% | -200.0% | 78.8% | 56.5% | — | 11.8% | -7.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-82.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.25 → -0.75
Residual
-82.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.